How do you select your first-line endocrine therapy to accompany CDK4/6 inhibitor in metastatic HR+ breast cancer?
Results with fulvestrant and letrozole backbone in MONALEESA and MONARCH trials seem comparable, but PALOMA data is somewhat mixed. How do these trials influence your decision on ET backbone?
Community PollStarted
How do you select your first-line endocrine therapy to accompany CDK4/6 inhibitor in metastatic HR+ breast cancer?
79 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · University Of Texas Southwestern Medical Center At Dallas
Answered on
If this is a denovo metastatic patient, my choice of endocrine therapy backbone will be an aromatase inhibitor. If the patient develops metastatic disease while on an AI, or within 6-12 months after completing or discontinuing an AI, I will consider fulvestrant. If there is evidence of an ESR1 mutat...
Join for free or sign in to see the full answer